LEGN PE Ratio & Valuation, Is LEGN Overvalued

Historical Valuation

Legend Biotech Corp (LEGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.87 is considered Undervalued compared with the five-year average of -26.57. The fair price of Legend Biotech Corp (LEGN) is between 1282.44 to 1526.51 according to relative valuation method. Compared to the current price of 20.27 USD , Legend Biotech Corp By Undervalued By 98.42%.

Relative Value

Fair Zone

1282.44-1526.51

Current Price：20.27

98.42%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Legend Biotech Corp (LEGN) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Legend Biotech Corp (LEGN) has a current Price-to-Book (P/B) ratio of 3.93. Compared to its 3-year average P/B ratio of 8.11, the current P/B ratio is approximately -51.56% higher. Relative to its 5-year average P/B ratio of 10.82, the current P/B ratio is about -63.68% higher. Legend Biotech Corp (LEGN) has a Forward Free Cash Flow (FCF) yield of approximately -4.75%. Compared to its 3-year average FCF yield of -3.09%, the current FCF yield is approximately 53.61% lower. Relative to its 5-year average FCF yield of -3.45%, the current FCF yield is about 37.83% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for LEGN competitors is 768.92, providing a benchmark for relative valuation. Legend Biotech Corp Corp (LEGN.O) exhibits a P/S ratio of 2.87, which is -99.63% above the industry average. Given its robust revenue growth of 64.26%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of LEGN increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of LEGN in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is LEGN currently overvalued or undervalued?

What is Legend Biotech Corp (LEGN) fair value?

LEGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Legend Biotech Corp (LEGN) is between 1282.44 to 1526.51 according to relative valuation method.

How does LEGN's valuation metrics compare to the industry average?

The average P/S ratio for LEGN's competitors is 768.92, providing a benchmark for relative valuation. Legend Biotech Corp Corp (LEGN) exhibits a P/S ratio of 2.87, which is -99.63% above the industry average. Given its robust revenue growth of 64.26%, this premium appears sustainable.

What is the current P/B ratio for Legend Biotech Corp (LEGN) as of Mar 12 2026?

As of Mar 12 2026, Legend Biotech Corp (LEGN) has a P/B ratio of 3.93. This indicates that the market values LEGN at 3.93 times its book value.

What is the current FCF Yield for Legend Biotech Corp (LEGN) as of Mar 12 2026?

As of Mar 12 2026, Legend Biotech Corp (LEGN) has a FCF Yield of -4.75%. This means that for every dollar of Legend Biotech Corp's market capitalization, the company generates -4.75 cents in free cash flow.

What is the current Forward P/E ratio for Legend Biotech Corp (LEGN) as of Mar 12 2026?

As of Mar 12 2026, Legend Biotech Corp (LEGN) has a Forward P/E ratio of -82.67. This means the market is willing to pay $-82.67 for every dollar of Legend Biotech Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Legend Biotech Corp (LEGN) as of Mar 12 2026?

As of Mar 12 2026, Legend Biotech Corp (LEGN) has a Forward P/S ratio of 2.87. This means the market is valuing LEGN at $2.87 for every dollar of expected revenue over the next 12 months.

LEGN Valuation